A push to protect kratom from federal regulation is picking up momentum inside the Trump administration, backed by two influential figures with financial and ideological stakes in the outcome.
Markwayne Mullin, a Republican congressman with equity holdings in a kratom company, and Robert F. Kennedy Jr., who heads the Health and Human Services department, are both championing the botanical substance as the industry seeks favorable policy treatment at the federal level.
Kratom, a plant derived from Southeast Asia, has exploded in popularity across American gas stations and online retailers. Advocates promote it as a natural alternative for pain and anxiety, while critics point to its opioid-like properties and potential for dependency. The substance occupies a regulatory gray zone, with some states moving to restrict it even as the federal government has stopped short of banning it outright.
The kratom industry has been working to lock in protections before any new restrictions materialize. The backing of Mullin and Kennedy Jr. provides the sector with rare access to policymaking circles, particularly as Republican leadership consolidates around Trump's second term.
Mullin's financial interest in a company positioned to profit from kratom's continued availability raises questions about the alignment of personal gain and policy advocacy. Kennedy Jr.'s involvement signals broader administration sympathy toward loosening oversight of unproven dietary substances, consistent with his wider skepticism of federal health agencies.
Author Sarah Mitchell: "The kratom industry has found an opening where ideology and self-interest converge, and that's a recipe for policies that prioritize profits over public health oversight."
Comments